Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dulaglutide - Eli Lilly and Company

Drug Profile

Dulaglutide - Eli Lilly and Company

Alternative Names: LY-2189265; Trulicity

Latest Information Update: 25 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antihyperglycaemics; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 21 Feb 2020 The US FDA approves dulaglutide for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple cardiovascular risk factors
  • 10 Oct 2019 Eli Lilly completes the phase III AWARD-11 trial in Type-2 diabetes mellitus (Adjunctive treatment) in USA, Puerto Rico, Romania, Poland, Mexico, Taiwan, Spain, Slovakia, Russia, Italy, Israel, Hungary, Greece, Canada, Austria and Argentina (NCT03495102)
  • 23 Sep 2019 Committee for Medicinal Products for Human Use (CHMP) approves positive opinion to update the label of Dulaglutide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top